Bugloss (Anchusa officinalis)

Anchusa officinalis, commonly called bugloss, contains pyrrolizidine alkaloids (including lycopsamine and intermedine) alongside allantoin and rosmarinic acid, which are thought to contribute to its traditional wound-healing and anti-inflammatory activity. Its primary mechanisms are attributed to allantoin's promotion of cell proliferation and rosmarinic acid's inhibition of pro-inflammatory mediators, though rigorous clinical evidence remains largely absent.

Origin & History

Bugloss (Anchusa officinalis) is a biennial or annual herbaceous plant native to Europe, particularly the Pindos mountains in Greece. It is harvested for its leaves, shoots, and roots to produce teas, ointments, or tinctures through drying processes.

Historical & Cultural Context

Bugloss has been used for over 2,000 years in European folk medicine, notably documented by Dioscorides for its astringent properties. It played a role in treating burns, ulcers, and various ailments in historical herbalism practices.

Health Benefits

• Potential diuretic effect via traditional herbal tea preparations, though not clinically validated. • Traditional use suggests benefits for skin issues such as ulcers and burns, based on historical records. • Folk medicine advocates its use for respiratory issues like coughs, without modern clinical evidence. • Historical claims of mood enhancement and relief from nervousness, unsupported by contemporary studies. • Anecdotal reports of aiding digestion and urinary issues, lacking scientific validation.

How It Works

Allantoin in Anchusa officinalis stimulates fibroblast proliferation and keratinocyte migration by upregulating growth factor signaling, supporting wound and ulcer healing at the tissue level. Rosmarinic acid inhibits cyclooxygenase (COX) enzymes and suppresses NF-κB pathway activation, reducing prostaglandin E2 synthesis and downstream inflammatory cytokine release. Pyrrolizidine alkaloids such as lycopsamine may exert mild diuretic effects through renal tubular modulation, though this pathway is not well characterized and carries hepatotoxicity risk.

Scientific Research

No human clinical trials or meta-analyses were identified for Anchusa officinalis. Searches on PubMed yielded no PMIDs related to clinical research; existing evidence is limited to traditional use and preliminary studies on related species.

Clinical Summary

No randomized controlled trials specifically investigating Anchusa officinalis in human subjects have been published in peer-reviewed literature as of 2024, leaving its therapeutic claims entirely within the domain of traditional and ethnobotanical evidence. In vitro studies have demonstrated anti-inflammatory activity of rosmarinic acid extracts, with COX-2 inhibition observed at concentrations of 10–50 µg/mL in cell culture models, but these findings have not been translated into human dose-response data. Animal models using topical allantoin preparations have shown accelerated wound closure rates of approximately 20–30% compared to controls, providing indirect support for the skin-healing tradition. The overall evidence base is very weak, and the presence of hepatotoxic pyrrolizidine alkaloids further limits enthusiasm for formal clinical investigation.

Nutritional Profile

Bugloss (Anchusa officinalis) is a non-staple medicinal herb with limited formal nutritional analysis; however, known compositional data includes: Bioactive compounds dominate its profile — pyrrolizidine alkaloids (including lycopsamine, intermedine, and their acetyl derivatives) are primary constituents, present at concentrations estimated 0.02–0.1% dry weight in aerial parts, with roots containing higher concentrations. Rosmarinic acid and other hydroxycinnamic acid derivatives serve as key phenolic antioxidants. Mucilaginous polysaccharides are present in moderate concentrations (~5–10% dry weight), contributing to its traditional use for soothing inflamed tissues. Tannins are present in small quantities (~1–3% dry weight), contributing astringent properties. Flavonoids including quercetin and kaempferol glycosides are present in trace-to-low amounts. Allantoin has been historically cited in related Boraginaceae species and may be present in minor quantities. Regarding conventional macronutrients: as a leafy herb, aerial parts contain primarily water (~85–90% fresh weight), with modest crude fiber (~2–4% fresh weight), minimal protein (~1–2% fresh weight), and negligible fat. Micronutrient data is sparse, but as a Boraginaceae member, modest potassium, calcium, and silica content is plausible. Bioavailability note: pyrrolizidine alkaloids are hepatotoxic and represent a significant safety concern, limiting therapeutic use; mucilage compounds have good bioavailability at mucosal surfaces.

Preparation & Dosage

Traditional preparations involve using 100g of dried leaves or roots in 1L of boiled water, consumed three times daily. No standardized doses are available. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Chamomile, Lemon Balm, St. John's Wort, Valerian, Lavender

Safety & Interactions

Anchusa officinalis contains unsaturated pyrrolizidine alkaloids (UPAs), including lycopsamine and intermedine, which are well-documented hepatotoxins capable of causing veno-occlusive disease with repeated or high-dose internal use, and the European Medicines Agency advises strict limits on UPA intake (maximum 0.35 µg/day for internal use). The herb is contraindicated during pregnancy and breastfeeding due to potential teratogenic and genotoxic effects of its pyrrolizidine alkaloid content. Concurrent use with hepatotoxic drugs (e.g., acetaminophen at high doses, statins, azathioprine) is inadvisable due to additive liver stress risk. External topical use is generally considered lower risk, but prolonged skin application over damaged skin may also allow systemic absorption of alkaloids, warranting caution.